{"schema_version":"secwatch.filing_event.v1","accession":"0001823239-23-000012","form_type":"8-K","ticker":"MRVI","cik":"0001823239","company_name":"MARAVAI LIFESCIENCES HOLDINGS, INC.","filed_at":"2023-02-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.813536+00:00","generated_at":"2026-06-19T05:22:43.006930+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Maravai Q4 revenue $204.7M, adj EPS $0.35; 2023 guidance $420-460M; acquires Alphazyme","bullets":["Q4 revenue $204.7M (-10% YoY); net income $87.4M; adjusted diluted EPS $0.35.","Full year 2022 revenue $883.0M (+10% YoY); net income $490.7M; adjusted EPS $1.80.","Base business revenue (ex-COVID CleanCap) up 67% in Q4 and 17% full year.","2023 revenue guidance $420M-$460M; base business growth expected >20%.","Acquired Alphazyme, LLC (private enzyme manufacturer); announced CEO succession plan."],"urls":{"canonical":"https://secwatch.observer/filing/0001823239-23-000012","json":"https://secwatch.observer/filing/0001823239-23-000012.json","markdown":"https://secwatch.observer/filing/0001823239-23-000012.md","text":"https://secwatch.observer/filing/0001823239-23-000012.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1823239/000182323923000012/0001823239-23-000012-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1823239/000182323923000012/mrvi-20230222.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T05:22:43.006930+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"767f24cb6bc7960981609fb00076c2879a510052","claim":"MARAVAI LIFESCIENCES HOLDINGS, INC. reported fourth quarter ended December 31, 2022 results: revenue $204.7 million, net income $87.4 million, EPS $0.35.","evidence_excerpt":"Quarterly revenue of $204.7 million, Net income of $87.4 million, and Adjusted fully diluted earnings per share (EPS) of $0.35","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1823239/000182323923000012/0001823239-23-000012-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter ended December 31, 2022"},{"label":"Revenue","value":"$204.7 million"},{"label":"Net income","value":"$87.4 million"},{"label":"EPS","value":"$0.35"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"987680698840dbe250b99665f511243bb05cfb15","claim":"MARAVAI LIFESCIENCES HOLDINGS, INC. reported full year ended December 31, 2022 results: revenue $883.0 million, net income $490.7 million, EPS $1.80.","evidence_excerpt":"Annual revenue of $883.0 million, Net income of $490.7 million and Adjusted fully diluted EPS of $1.80","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1823239/000182323923000012/0001823239-23-000012-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year ended December 31, 2022"},{"label":"Revenue","value":"$883.0 million"},{"label":"Net income","value":"$490.7 million"},{"label":"EPS","value":"$1.80"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"cef2d6e6a265dd7748c27ce1be14e819cd6e3220","claim":"MARAVAI LIFESCIENCES HOLDINGS, INC. reported full year 2023 results: revenue $420.0 million to $460.0 million. Guidance initiated.","evidence_excerpt":"Introduced 2023 revenue guidance range of $420.0 million to $460.0 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1823239/000182323923000012/0001823239-23-000012-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year 2023"},{"label":"Revenue","value":"$420.0 million to $460.0 million"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}